| Gene symbol | TERT | Synonyms | CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5p15.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | telomerase reverse transcriptase | ||||
| GTO ID | GTC3971 |
| Trial ID | NCT03172819 |
| Disease | Advanced Solid Tumor |
| Altered gene | E1A|E1B|TERT |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | Telomelysin|OBP-301 |
| Co-treatment | Pembrolizumab |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors |
| Year | 2017 |
| Country | Japan |
| Company sponsor | Toshihiko Doi |
| Other ID(s) | EPOC1505 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||||
|
|||||||||